DHSC: OHID: Metachromatic Leukodystrophy (MLD) Evidence Map

Department of Health and Social Care (T&T)contractContracts FinderRef CF-1430100D0O000000rwimUAASME suitableVCSE suitablecomplete

Estimated value

£16k

Awarded value

£16k

Awarded 20 Mar 2023

Suppliers

1

Lots

1

1 awarded

Published

20 Mar 2023

Deadline 28 Feb 2023

Other contracts from Department of Health and Social Care (T&T)· 10

Most recent notices published by the same contracting authority.

View buyer profile →
TitleTypeValuePublished
NHS Pensions McCloud Programme Management Supportcontract£1.4m28 Apr 2026
DHSC: Technical Advisor support for new Private Finance Programmecontract£735k27 Apr 2026
DHSC:FGO NHSE Transformation Programme - Communications Integrationcontract£51k22 Apr 2026
DHSC: MedTech - Compass Alphacontract£575k21 Nov 2025
DRW Samba II Reagentcall off£95.5m27 Apr 2023
Provision of Lateral Flow testing devices for the detection of COVID-19 viral ancall off£325.2m26 Apr 2023
IT Test Supply Chain - PCR Kitting Emergency Ramp Upcall off£1.0m26 Apr 2023
Automated Kitting Providers Capability Assessment Servicecall off£22k14 Apr 2023
Digital Outcome & Specialists - Service Deliverycall off£1.5m14 Apr 2023
NHS SBS Commercial Resourcescall off£976k14 Apr 2023

Other contracts awarded to COSTELLO MEDICAL CONSULTING LIMITED· 10

Cross-buyer view of this supplier's public-sector wins.

View supplier profile →
TitleTypeValuePublished
Health Economics Feasibility Study- Specialised Commissioningcontract£24k17 Oct 2023
C149851_DHSC: OHID: Anorectal malformations Evidence Mapcontract£17k24 Mar 2023
Consultancy Services for Population Health Programmecontract£44k29 Nov 2022
Evidence Map on Screening for Cytomegaloviruscontract£50k18 Jun 2021
PHE - Corporate - Evidence Map on Biotinidase Deficiencycontract£6k09 Jun 2021
PHE - Corporate - Asymptomatic Bacteriuria Screening in Pregnancycontract£81k26 May 2021
PHE - Corporate - Evidence Map on Neuronal Ceroid Lipofuscinosis Type 2contract£11k21 Apr 2021
PHE - Corporate - Screening for Duchenne Muscular Dystrophycontract£15k31 Mar 2021
PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Majorcontract£81k03 Nov 2020
PHE - Corporate - Ultrasound Screening for Fetal Presentation at 36 Weekscontract£11k02 Sept 2020